MX2022013054A - Derivados de imidazolidinona y uso medico de los mismos. - Google Patents

Derivados de imidazolidinona y uso medico de los mismos.

Info

Publication number
MX2022013054A
MX2022013054A MX2022013054A MX2022013054A MX2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A
Authority
MX
Mexico
Prior art keywords
medicine
derivative
present application
imidazolinone
imidazolinone derivative
Prior art date
Application number
MX2022013054A
Other languages
English (en)
Inventor
Jie Yan
Yang He
Yonggang Wei
Bing Liu
Hongzhu Chu
Guizhuan Su
Meiwei Wang
Yi Sun
Xuezhen Xu
Lvxue He
Feiquan Lei
Original Assignee
Chengdu Baiyu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Baiyu Pharmaceutical Co Ltd filed Critical Chengdu Baiyu Pharmaceutical Co Ltd
Publication of MX2022013054A publication Critical patent/MX2022013054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se relaciona con derivados de imidazolidinona y su uso médico, y en particular se relaciona con derivados de pirimidina representados por la fórmula general (I), o estereoisómeros, solvatos, metabolitos, profármacos, sales farmacéuticamente aceptables o cocristales de los mismos, una composición farmacéutica que comprende éstos, y el uso del compuesto o composición farmacéutica según la presente solicitud en la fabricación de un medicamento para el tratamiento del cáncer. (ver Fórmula).
MX2022013054A 2020-04-17 2021-04-16 Derivados de imidazolidinona y uso medico de los mismos. MX2022013054A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010302603 2020-04-17
CN202010679647 2020-07-15
CN202110360821 2021-04-02
PCT/CN2021/087912 WO2021209055A1 (zh) 2020-04-17 2021-04-16 咪唑啉酮衍生物及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2022013054A true MX2022013054A (es) 2022-11-09

Family

ID=78083933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013054A MX2022013054A (es) 2020-04-17 2021-04-16 Derivados de imidazolidinona y uso medico de los mismos.

Country Status (11)

Country Link
US (1) US20230165867A1 (es)
EP (1) EP4137491A4 (es)
JP (1) JP7498795B2 (es)
KR (1) KR20230004697A (es)
CN (1) CN114315834B (es)
AU (1) AU2021256235B2 (es)
BR (1) BR112022020962A2 (es)
CA (1) CA3175589A1 (es)
MX (1) MX2022013054A (es)
WO (1) WO2021209055A1 (es)
ZA (1) ZA202211870B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
TWI823531B (zh) * 2021-08-23 2023-11-21 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物或者其立體異構體的製備方法及其中間體
TWI826013B (zh) * 2021-09-23 2023-12-11 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物的晶型
WO2024012516A1 (zh) * 2022-07-13 2024-01-18 成都百裕制药股份有限公司 咪唑啉酮衍生物在联合放疗治疗肿瘤中的应用
WO2024017220A1 (zh) * 2022-07-20 2024-01-25 成都百裕制药股份有限公司 咪唑啉酮衍生物联合多柔比星在治疗肿瘤中的应用
WO2024125304A1 (zh) * 2022-12-13 2024-06-20 成都百裕制药股份有限公司 一种咪唑啉酮类化合物药物制剂及其制备方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
DK3459942T3 (da) 2012-04-24 2021-03-08 Vertex Pharma DNA-PK-hæmmere
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
TW201526894A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 藉二氫吡并吡治療癌症
AU2017384388B2 (en) 2016-12-20 2020-09-17 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
EP4137491A1 (en) 2023-02-22
KR20230004697A (ko) 2023-01-06
ZA202211870B (en) 2023-05-31
WO2021209055A1 (zh) 2021-10-21
EP4137491A4 (en) 2024-05-08
US20230165867A1 (en) 2023-06-01
JP2023521923A (ja) 2023-05-25
AU2021256235A1 (en) 2022-11-17
JP7498795B2 (ja) 2024-06-12
CA3175589A1 (en) 2021-10-21
CN114315834B (zh) 2024-01-05
AU2021256235B2 (en) 2024-05-09
CN114315834A (zh) 2022-04-12
BR112022020962A2 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MX2022008066A (es) Compuestos triciclicos sustituidos.
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2020000268A (es) Agonista de fxr.
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
ZA202306652B (en) Five-membered ring derivative and medical use thereof
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
MX2021003724A (es) Profarmaco de nitroxolina y su uso.
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2024000807A (es) Inhibidor de aak1 y uso de este.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2018008799A (es) Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2021015827A (es) Antagonista de neurokinin -1.
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
AU2015204609B2 (en) Novel functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy